Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
69.44
-1.16 (-1.64%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about BioMarin Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
1 Healthcare Stock to Target This Week and 2 to Turn Down
March 11, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...
Via
StockStory
Topics
Stocks
Exposures
COVID-19
US Equities
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
March 11, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
March 10, 2025
BIOMARIN PHARMACEUTICAL INC has a stellar value proposition. NASDAQ:BMRN not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
Via
Chartmill
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
March 04, 2025
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews
February 20, 2025
Via
Benzinga
Earnings Scheduled For February 19, 2025
February 19, 2025
Via
Benzinga
NASDAQ:BMRN, a growth stock which is not overvalued.
December 24, 2024
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via
Chartmill
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
February 25, 2025
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.
Via
StockStory
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
February 25, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know.
Via
StockStory
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
February 23, 2025
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.
Via
StockStory
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
February 20, 2025
Via
The Motley Fool
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
February 20, 2025
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS...
Via
StockStory
The Latest Analyst Ratings For Biomarin Pharmaceutical
December 12, 2024
Via
Benzinga
Why Is BioMarin Stock Trading Higher On Thursday?
February 20, 2025
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.
Via
Benzinga
BioMarin: EPS Surges Past Expectations
February 19, 2025
BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.
Via
The Motley Fool
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars
February 19, 2025
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year...
Via
StockStory
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
February 18, 2025
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.
Via
StockStory
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
February 13, 2025
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
Via
Benzinga
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
November 15, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 12, 2025
Via
Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
February 04, 2025
NASDAQ:BMRN is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Via
Chartmill
NASDAQ:BMRN is an undervalued gem with solid fundamentals.
January 27, 2025
Take a closer look at BIOMARIN PHARMACEUTICAL INC , a remarkable value stock. NASDAQ:BMRN excels in fundamentals and maintains a very reasonable valuation.
Via
Chartmill
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
January 19, 2025
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,...
Via
Benzinga
NASDAQ:BMRN is showing decent growth, but is still valued reasonably.
January 14, 2025
Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
January 08, 2025
Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb.
Via
Benzinga
Topics
ETFs
10 Magnificent Stocks That Can Make You Richer in 2025
January 03, 2025
A new year brings with it new opportunities to grow your wealth on Wall Street.
Via
The Motley Fool
NASDAQ:BMRN stands out as a stock that provides good value for the fundamentals it showcases.
December 27, 2024
In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
December 02, 2024
Despite its growth, NASDAQ:BMRN remains within the realm of affordability.
Via
Chartmill
When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
November 22, 2024
In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
November 22, 2024
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.